Abstract:Zhihong Liu, 1, 2, &ast Xiaofang Liang, 1, &ast Yu Zhang, 1 Wenbo Deng, 1 Yulin Wang, 3 Zhangping Lu, 2 Qianqian Liu, 2 Lianhua Wei 2 1 School of Public Health, Gansu University of Traditional Chinese Medicine, Lanzhou, Gansu, People's Republic of China; 2 Department of Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, Gansu, People's Republic of China; 3 Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lianhua Wei, Email The development of antibiotic resistance complicates the treatment of infectious diseases and is a global public health threat. However, drug repurposing can address this resistance issue and reduce research and development costs. Niclosamide is a salicylanilide compound approved by the Food and Drug Administration (FDA), and it has been used clinically for treating parasitic infections for many years. Recent studies have shown that niclosamide can inhibit bacterial and fungus activity by affecting the quorum sensing system, biofilm formation, cell membrane potential, and other mechanisms. Here, we discuss recent advances in the antimicrobial applications of niclosamide and its derivatives to provide new perspectives in treating infectious diseases. Keywords: antimicrobial resistance, multi-drug resistance, niclosamide, a derivative, drug repurposing Antibiotics have been used to treat bacterial infections for over 70 years and have been the most important class of drugs since the twentieth century. 1 However, excessive or inappropriate use of antibiotics has led to the emergence of antimicrobial resistance (AMR) and the production of multidrug-resistant (MDR) bacteria in the clinic, in animals, and even in the environment. 2 Experts estimate that AMR could force 24 million people into extreme poverty by 2030 and that MDR bacterial infections could cause 10 million deaths per year worldwide by 2050. 3 The search for new antibiotics for clinical use is becoming increasingly challenging due to the significant costs associated with drug development and the rapid emergence of drug resistance. 4 Drug repurposing is a creative strategy to address this problem. This strategy has been successfully applied to the discovery of potential treatments for a wide range of diseases, including infectious diseases. In recent years, it has been shown that, among non-antimicrobial drugs, auranofin 5 and ebselen 6 are active against many kinds of bacteria by inhibiting thioredoxin reductase (TrxR), while NIC kills microorganisms by inhibiting mechanisms such as quorum sensing systems and biofilm formation. It has attracted wide attention due to NIC's strong antibacterial activity, inhibit many kinds of bacteria, and the fact that it is not easy to develop drug resistance. NIC, a clinical antiparasitic drug approved by the FDA in 1982, works as a hydrogen ionophore that plays a role. NIC inhibits adenosine triphosphate (ATP) production through oxidative phosphorylation and uncoupling of electron transfer, leading to parasite death. 7 Over the past decades, evidence has shown that NIC can also act on other targets, such as the Wnt/β-catenin, mTOR, and JAK/STAT3 signaling pathways. 8 These pathways play an essential role in developing and progressing many diseases. The versatility of NIC has been increasingly demonstrated, while its potential in treating infectious diseases has been progressively discovered. In this paper, by searching for relevant literature in globally recognized databases such as PubMed, Web of Science, and Google Scholar. For the first time, the antibacterial and antifungal activities and mechanisms of action of NIC and its derivatives are reviewed. In addition, a brief summary of the application of NIC in other medical fields was provided. Finally, the shortcomings and perspectives of NIC and its derivatives are discussed. New ideas for the pharmaceutical reuse of NIC are provided. NIC, also known as Bayluscide, is an odorless, water-insoluble, yellowish-white crystalline powder. In the late 1950s, Bayer first discovered through screening that NIC could control Schistosoma mansoni transmission and developed and marketed it as a molluscicide. 9 In 1960, Bayer scientists discovered that it also played an essential role in controlling parasitic infections in humans. In 1962, it was marketed for human use under the trade name Yomesan. 10 The FDA added NIC to the World Health Organization (WHO) list of essential drugs in 1982. 11 Structurally, NIC belongs to a large group of lipophilic, weakly acidic molecules called salicyl -Abstract Truncated-

Novel Derivatives of Niclosamide Synthesis: Its Bioactivity and Interaction with Schistosoma Japonicum Cercariae

Superior Anticancer and Antifungal Activities of New Sulfanyl-Substituted Niclosamide Derivatives

Synthesis, cytotoxicity, and pharmacokinetic evaluations of niclosamide analogs for anti-SARS-CoV-2

[Sythesis and Antischistosomal Action of Phenithionate and Related Derivatives of Thiocarbamic Acid].

Drug Repurposing: Research Progress of Niclosamide and Its Derivatives on Antibacterial Activity

Niclosamide: Beyond an antihelminthic drug

Design, synthesis, crystal structure, bioactivity, and molecular docking studies of novel sulfonylamidine-derived neonicotinoid analogs

Targeting the Schistosoma mansoni nutritional mechanisms to design new antischistosomal compounds

Anti-Schistosomal Activity and ADMET Properties of 1,2,5-Oxadiazinane-Containing Compound Synthesized by Visible-Light Photoredox Catalysis

Synthesis and antifungal activities of novel nicotinamide derivatives containing 1,3,4-oxadiazole

Structural diversity derivatization and studies on the nematicidal activity of tropane derivatives

Design, synthesis, and nematicidal activity of novel 1,2,4-oxadiazole derivatives containing amide fragments

Synthesis and Bioactivity Evaluation of Novel N -Pyridylpyrazolemethanamine Derivatives

Design, Green Synthesis, and Anticancer Activity of Novel Nicotinonitrile Derivatives

Novel Sophoridine Derivatives as Potential Larvicidal Agents against Aedes albopictus: Synthesis, Biological Evaluation, Acetylcholinesterase Inhibition, and Morphological Study

Sulfonamide modified chitosan oligosaccharide with high nematicidal activity against Meloidogyne incognita

Novel bis(2‐cyanoacrylamide) linked to sulphamethoxazole: Synthesis, DNA interaction, anticancer, ADMET, molecular docking, and DFT studies

Synthesis and Larvicidal Activity of Novel Thenoylhydrazide Derivatives.

Synthesis and Biological Evaluation of Cyanoacrylamides and 5-Iminopyrrol-2-Ones Against Naegleria fowleri

Synthesis, nematocidal activity and SAR study of novel difluoromethylpyrazole carboxamide derivatives containing flexible alkyl chain moieties

JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both In Vitro and In Vivo